PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1473817
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1473817
Progesterone Market Size - By Formulation (Natural, Synthetic), Route of Administration (Injectable, Oral), Application (Contraception, Menopause), Drug Type (Generic, Branded), Type (Prescription, OTC), Distribution Channel & Forecast, 2024 - 2032
Progesterone market size is estimated to witness 12.7% CAGR between 2024 and 2032, owing to increasing awareness and diagnosis of hormone-related disorders, such as polycystic ovary syndrome (PCOS), infertility, and menstrual irregularities. As per WHO, in 2023, PCOS affected an estimated 8 to 13% of reproductive-aged women, with up to 70% of the affected women remaining undiagnosed worldwide. Healthcare providers are increasingly prescribing progesterone medications to address these conditions. The aging population and rising instances of menopausal symptoms are further necessitating hormone replacement therapies.
Moreover, advancements in pharmaceutical formulations and drug delivery technologies are enhancing the efficacy and safety profile of progesterone products, fostering their adoption in clinical settings. Innovations, such as sustained-release formulations and transdermal patches offer convenient administration routes and improved patient compliance. The expanding research activities focused on exploring the therapeutic potential of progesterone in areas like cancer treatment, neurology, and psychiatry will also drive the market growth.
The progesterone industry is classified on the basis of formulation, route of administration, application, drug type, type, distribution channel, and region.
By application, the market size from the contraception segment is poised to witness 13.1% CAGR from 2024 to 2032. This is driven by the increasing global emphasis on family planning initiatives and the growing acceptance of hormonal contraceptives among women. The ongoing R&D efforts aimed at enhancing the safety, efficacy, and convenience of progesterone-based contraceptives are also offering lucrative opportunities for the product manufacturers and stakeholders.
Based on type, the progesterone industry from the OTC segment will record 12.4% CAGR during 2024-2032. The growth is favored by the increasing consumer awareness and empowerment regarding women's health, coupled with the convenience of access to OTC products. Furthermore, the availability of progesterone creams, gels, and supplements without the need for a prescription offers greater autonomy in managing hormone-related conditions, thereby expanding the consumer base.
Asia Pacific progesterone industry is slated to witness a 12.3% growth rate through 2032, attributed to the burgeoning population, coupled with increasing awareness and access to healthcare services to address hormone-related disorders, such as PCOS and infertility. The cultural shifts towards smaller family sizes and delayed childbearing are contributing to the rising adoption of hormonal contraceptives containing progesterone. Additionally, the presence of a robust pharmaceutical manufacturing sector in India and China will foster the local production of progesterone medications for ensuring supply chain resilience and affordability, stimulating the regional industry growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data validation
- 1.4 Forecast parameters
- 1.5 Data sources
- 1.5.1 Primary
- 1.5.2 Secondary
- 1.5.2.1 Paid sources
- 1.5.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of hormonal disorders
- 3.2.1.2 Rising awareness about women's health
- 3.2.1.3 Favorable government initiatives and healthcare policies
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Formulation, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Natural
- 5.3 Synthetic
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Injectable
- 6.3 Oral
- 6.4 Transdermal
- 6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Menopause
- 7.3 Contraception
- 7.4 Dysfunctional uterine bleeding
- 7.5 Hyperplastic precursor lesions
- 7.6 Endometrial cancer
- 7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Branded
- 8.3 Generic
Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)
- 9.1 Prescription
- 9.2 OTC
Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 Hospital pharmacy
- 10.3 Retail pharmacy
- 10.4 Online pharmacy
Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 11.1 Key trends
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 Rest of Asia Pacific
- 11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
- 11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 Rest of Middle East and Africa
Chapter 12 Company Profiles
- 12.1 Alkem Laboratories Ltd.
- 12.2 Aquatic Group
- 12.3 Bionpharma Inc.
- 12.4 Cadila Pharmaceuticals
- 12.5 Cipla Inc.
- 12.6 Estrellas Life Sciences Private Limited.
- 12.7 Eli Lily & Company
- 12.8 Glenmark Pharmaceuticals Ltd.
- 12.9 Insud Pharma S.L.U.
- 12.10 Lupin
- 12.11 Novo Nordisk A/S
- 12.12 Teva Pharmaceutical Industries Ltd
